NIHR Clinical Research Facility: Sheffield

Between 1 April 2026 and 31 March 2027, the following articles were published which relate to studies that have been supported by the NIHR Clinical Research Facility (CRF): Sheffield.

The UK vedolizumab real-life experience study in inflammatory bowel disease (VEST): patient characteristics, drug persistence and patient-centred outcomes (STH19954: VEST)

Investigating prognostic classifications of preexisting multiple long-term conditions for health outcomes 1 year after COVID-19 hospitalization: A UK prospective observational study (STH21439: PHOSP-COVID)

Efficacy, safety, and immunogenicity of a nine-valent vaccine (ExPEC9V) for the prevention of invasive Escherichia coli disease in older adults: a phase 3, randomised, placebo-controlled trial (E.mbrace) (STH21886: E.mbrace)

ChAdOx1 nCoV-19 coronavirus vaccine: Long-term safety and immunological responses (STH21900: COV009)

Azurocidin-1 as a mediator of bronchiectasis severity, epithelial defence, and target of dipeptidyl peptidase-1 inhibition: an international, multicohort study (STH23441: BRIDGE study)